Nexentis Techgnologies Inc (NXTS)

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative

MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules...

Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)

Nexentis Technologies Inc. (NASDAQ:NXTS) shares advanced 10% on Monday after the company announced the partial monetisation of its investment in...

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis”...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery

MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic...

Nexentis Shares Swing After Subsidiary Reaches Drug Discovery Research Milestone

Nexentis Technologies Inc. (NASDAQ:NXTS) experienced sharp trading volatility on Wednesday after announcing a research breakthrough at its...

Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases

Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Form 8-K - Current report

Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development

Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone

MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future...

Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™

Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis”...